

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization

International Bureau

(43) International Publication Date  
02 November 2023 (02.11.2023)



(10) International Publication Number  
**WO 2023/212675 A1**

(51) International Patent Classification:

G01N 33/50 (2006.01) C07K 14/725 (2006.01)  
A61K 35/17 (2015.01) C07K 14/74 (2006.01)

DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2023/066340

(22) International Filing Date:

28 April 2023 (28.04.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/336,068 28 April 2022 (28.04.2022) US  
63/486,776 24 February 2023 (24.02.2023) US

(71) Applicant: **ALLOGENE THERAPEUTICS INC.**  
[US/US]; 210 East Grand Avenue, South San Francisco,  
California 94080 (US).

(72) Inventors: **LIN, Meng-Yin**; c/o Allogene Therapeutics,  
Inc., 210 E. Grand Avenue, South San Francisco, Califor-  
nia 94080 (US). **YOON, Hayung**; 3827 California Street,  
San Francisco, California 94118 (US). **PERTEL, Thomas  
Charles**; 1646 Bayridge Way, San Mateo, California 94402  
(US). **SASU, Barbra Johnson**; c/o Allogene Therapeutics,  
Inc., 210 E. Grand Avenue, South San Francisco, California  
94080 (US).

(74) Agent: **BERNHARDT, Jeffery P.** et al.; c/o Allogene  
Therapeutics, Inc., Legal IP, 210 E. Grand Avenue, South  
San Francisco, California 94080 (US).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,  
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,  
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,  
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,  
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,  
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,  
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,  
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,  
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, CV,  
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,  
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,  
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: METHODS FOR DONOR CELL ANALYSIS

(57) Abstract: Provided herein are methods, kits and reagents for analyzing the attributes of cell populations, such as donor cells prior to modification to provide engineered cells, e.g., engineered immune cells, such as CAR T cells. For example, provided herein are methods of determining the amount or percentage of biomarkers and/or secretion profiles of donor cell populations, selecting donor cells with certain biomarkers and/or secretion profiles, and engineering the CAR T cells from the selected donor cells.

WO 2023/212675 A1